Guggenheim initiated coverage of Entrada Therapeutics (TRDA) with a Buy rating and $20 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics initiated with an Outperform at Oppenheimer
- Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
- Entrada Therapeutics highlights RNA pipeline progress and outlook
- Entrada Therapeutics reports progress across development portfolio